 This is an open label, 16 week study of apremilast in combination with topical corticosteroids TCS. Twenty qualified subjects will be enrolled. Visits will consist of Baseline, 8 week, 16 week and a 20 week safety follow up after 4 weeks off treatment. Subjects will dose with apremilast as per label. Topical corticosteroids TCS will be used for up to Week 4 as per label and then will be used on an as needed basis until Week 16. Assessments will include Static Physicians Global Assessment sPGA, Psoriasis Area Severity Index PASI, Psoriatic Body Surface Area BSA, Dermatology Life Quality Index DLQI,Assessment of Pruritus, Patient Satisfaction questionnaire. and Patient Global Assessment PtGA 